Biocatalytic Routes to Enantiomerically Enriched Dibenz[c, e]azepines. (7th November 2017)

• Record Type: Journal Article
• Authors: France, Scott P.; Aleku, Godwin A.; Sharma, Mahima; Mangas‐Sanchez, Juan; Howard, Roger M.; Steflik, Jeremy; Kumar, Rajesh; Adams, Ralph W.; Slabu, Iustina; Crook, Robert; Grogan, Gideon; Wallace, Timothy W.; Turner, Nicholas J.
• Is Part Of: Angewandte Chemie. Volume 129:Number 49(2017)
• Page Start: 15795
• Page End: 15799
• Publication Date: 2017-11-07
• Subjects: Biokatalyse -- Heterocyclen -- Reduktasen -- Synthesemethoden -- Transaminasen; Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.201708453
• Languages: English
• ISSNs: 0044-8249

Abstract

Abstract: Biocatalytic retrosynthetic analysis of dibenz[c, e]azepines has highlighted the use of imine reductase (IRED) and ω‐transaminase (ω‐TA) biocatalysts to establish the key stereocentres of these molecules. Several enantiocomplementary IREDs were identified for the synthesis of ( R )‐ and ( S )‐5‐methyl‐6, 7‐dihydro‐5 H ‐dibenz[c, e]azepine with excellent enantioselectivity, by reduction of the parent imines. Crystallographic evidence suggests that IREDs may be able to bind one conformer of the imine substrate such that, upon reduction, the major product conformer is generated directly. ω‐TA biocatalysts were also successfully employed for the production of enantiopure 1‐(2‐bromophenyl)ethan‐1‐amine, thus enabling an orthogonal route for the installation of chirality into dibenz[c, e]azepine framework.